28

Jul2017

Release of PMPRB Annual Report Delayed (Again) – So much for transparency…

The release of the Patented Medicine Prices Review Board (PMPRB) Annual Report is delayed once again this year - so much for transparency and the PMPRB’s mission statement to “provide stakeholders with price, cost, and utilization information to help them make timely and knowledgeable drug pricing, purchasing, and reimbursement ... Read More

25

Jul2017

2018 HDAP Meeting Schedule

The following table provides the submission deadlines for the HDAP meetings in 2018: HDAP Meeting Date Filing Deadlines Product Monograph (1) Submission (2) February 27, 2018 November 7, 2017 December 12, 2017 May 7, 2018... Read More

14

Jul2017

CADTH Common Drug Review Releases New Update

On July 13, 2017, the Canadian Agency for Drugs and Technologies in Health (CADTH) released a new CDR Update (Issue 124) describing the following changes. CDEC Meeting Added in December 2017 and Updated CDEC Meeting Dates CADTH will be holding a Canadian Drug Expert Committee (CDEC) meeting in December 2017 ... Read More

13

Jul2017

Ontario Drug Benefit Act to Create and Implement OHIP+: Children and Youth Pharmacare Program

On July 11, 2017, the Executive Officer announced that as part of the 2017 Budget and the government’s ongoing commitment to provide better and faster access to high-quality health services, Ontario is proposing to create the OHIP+: Children and Youth Pharmacare Program. Under this program, the province would, as of January ... Read More

11

Jul2017

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of June 30, 2017: 42 negotiations are currently underway with 6 new files added since the last update of May 31, 2017: Caprelsa (vandetanib): Used to treat medullary thyroid cancer Kyprolis (carfilzomib): Used to ... Read More

15

Jun2017

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of May 31, 2017: 43 negotiations are currently underway with 9 new files added since the last update of April 30, 2017: Brivlera (brivarcetam): Used to treat partial-onset seizures Butrans (buprenorphine): Used to treat ... Read More

13

Jun2017

UPDATE: Québec – INESSS Submission Deadline for August 2017

The Minister of Health and Social Services has authorized one additional update to the List of Medications covered by the basic prescription drug insurance plan and the List of Medications – Institutions in 2018: February 1. The submission deadline for innovative drug products is August 11, 2017. Please note that only ... Read More

09

Jun2017

CADTH Common Drug Review Releases New Update

On June 9, 2017, the Canadian Agency for Drugs and Technologies in Health (CADTH) released a new CDR Update (Issue 122) describing the following changes. 1. Revised Advanced Notification Process for CADTH Common Drug Review Drugs Undergoing Expedited Health Canada Review Effective immediately, the mandatory advance notification requirement for drugs that are ... Read More

09

Jun2017

PDCI Market Access Webinar: Information Session for Industry on New INESSS Submission Guidelines and Implementation of Pre-NOC Review Procedure

On June 2, 2017, Québec’s Institut national d’excellence en santé et en services sociaux (INESSS) released new submission guidelines, including a pre-NOC review procedure, to be implemented immediately. Topics to be covered include: New Pre-NOC Review Procedure & Submission Criteria New Submission Guidelines New Submission Requirements Potential Changes to List ... Read More

06

Jun2017

NEW: INESSS Releases New Submission Guidelines – Implementation of Pre-NOC Review Procedure

On June 2, 2017, Québec’s Institut national d’excellence en santé et en services sociaux (INESSS) released new submission guidelines, including a pre-NOC review procedure, to be implemented immediately. Pre-NOC Review Moving forward, INESSS will evaluate certain drug products (see the criteria here on the INESSS website) before a Notice of Compliance ... Read More